Alumis(ALMS)

View 10 open jobs Website LinkedIn Careers Page

Focus: Alumis is a publicly traded biotechnology company focused on autoimmune treatments, specifically targeting immunology indications like psoriasis and uveitis. Founded in 2010 and headquartered in South San Francisco, the company operates as a clinical-stage biotech with an unusually high R&D intensity.

Immunology

Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

10-5 this month

Cooling — net -5 jobs in 30d

4 added, 9 removed. Slower than typical.

Should You Work at Alumis?

AI assessment

Best suited for early-to-mid career professionals seeking high-growth biotech exposure in immunology with near-term clinical catalysts, provided they accept pre-commercial risk and potential restructuring if Phase 3 programs underperform.

Why Work Here

Heavy pipeline investment: 13 active clinical trials across Phase 1-3 with two Phase 3 programs (envudeucitinib and ESK-001 for psoriasis) approaching near-term catalysts.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$24M

Pipeline & Clinical Trials

ESK-001

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT06952634An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Phase 1

Help build intelligence for Alumis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Rapid financial scaling: R&D spending nearly doubled from $138M (FY2024) to $266M (FY2025), signaling aggressive advancement of lead assets and expansion of research capability.

Immunology focus with large addressable market: psoriasis and uveitis are well-validated therapeutic areas with clear competitive benchmarks (Amgen's Tepezza mentioned in recent news).

Watch Out For

Pre-revenue stage with widening losses: $24M revenue in FY2025 against $294M net loss and only $170M cash; runway sustainability depends on capital markets or partnership.
Recent strategic retreat: May 2026 news indicates Alumis pulled back from a would-be rival program, signaling potential deprioritization or resource constraints on less-favored assets.

Generated by Claude from Alumis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ESK-001

Renal Impairment

Phase 1

Clinical Trials (1)

NCT06962774An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Phase 1

A-005

Safety and Tolerability

Phase 1

Clinical Trials (1)

NCT07442149An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

Phase 1

ESK-001

Pharmacokinetics

Phase 1

Clinical Trials (3)

NCT05739435Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Phase 2

NCT05966480Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Phase 2

NCT05330858Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Phase 1

Experimental drug: ESK-001

Safety and Tolerability

Phase 1

Clinical Trials (1)

NCT05431634Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

Phase 1

ESK-001

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT07378579An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

Phase 1

ESK-001

Plaque Psoriasis

Phase 2

Clinical Trials (1)

NCT05600036A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Phase 2

ESK-001

Uveitis Posterior Non-Infectious

Phase 2

Clinical Trials (1)

NCT05953688POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

Phase 2

envudeucitinib

Plaque Psoriasis

Phase 3

ESK-001

Plaque Psoriasis

Phase 3

Clinical Trials (1)

NCT06588738A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

Phase 3

Open-Label ESK-001

Plaque Psoriasis

Phase 3

Clinical Trials (1)

NCT06846541Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Phase 3

ESK-001

Plaque Psoriasis

Phase 3

Clinical Trials (1)

NCT06586112A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

Phase 3

Interview Prep Quick Facts

Founded: 2010

Portfolio: 13 clinical trials

Top TAs: Immunology, Gastroenterology, Nephrology

Publications: 8 in PubMed

SEC Filings: 2 available

Open Roles: 10 active jobs

Therapeutic Area Focus

5 pipeline

1 pipeline

1 pipeline

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$24M

R&D Spend

$266M(1104%)93%

Net Income

-$294M

Cash

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Research Publications(8)

Recent peer-reviewed publications with author affiliations at this company

Lonigutamab Inhibits Hyaluronan Production by Reducing IGF-1R Levels in Thyroid Eye Disease Orbital Fibroblasts.

The Journal of clinical endocrinology and metabolism

2026

PMID:42504937

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.

Dermatology and therapy

Showing 5 of 8 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Alumis(ALMS)

Should You Work at Alumis?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Alumis(10)

Open Jobs (10)

Medical Outcomes Liaison

Senior Director, Medical Strategy and Operations

Financials (FY2025)

Hiring Trend

Research Publications(8)